Results 21 to 30 of about 8,790,513 (336)

Lipid-Lowering Strategies for Primary Prevention of Coronary Heart Disease in the UK: A Cost-Effectiveness Analysis

PharmacoEconomics (Auckland), 2023
We aimed to assess the cost effectiveness of four different lipid-lowering strategies for primary prevention of coronary heart disease initiated at ages 30, 40, 50, and 60 years from the UK National Health Service perspective.
J. Morton, C. Marquina, Melanie Lloyd, G. Watts, S. Zoungas, D. Liew, Z. Ademi   +6 more
semanticscholar   +1 more source

Nonparametric inference for time‐dependent incremental cost‐effectiveness ratios [PDF]

Statistics in Medicine, 2015
As the costs of medical care increase, more studies are evaluating cost in addition to effectiveness of treatments. Cost‐effectiveness analyses in randomized clinical trials have typically been conducted only at the end of follow‐up. However, cost‐effectiveness may change over time.
Laura M, Yee, Kwun Chuen, Gary Chan
openaire   +2 more sources

Median-based incremental cost-effectiveness ratios with censored data [PDF]

Journal of Biopharmaceutical Statistics, 2015
Cost-effectiveness is an essential part of treatment evaluation, in addition to effectiveness. In the cost-effectiveness analysis, a measure called the incremental cost-effectiveness ratio (ICER) is widely utilized, and the mean cost and the mean (quality-adjusted) life years have served as norms to summarize cost and effectiveness for a study ...
Bang, Heejung, Zhao, Hongwei
openaire   +4 more sources

Cost-effectiveness evidence of mental health prevention and promotion interventions: A systematic review of economic evaluations

PLoS Medicine, 2021
Background The prevention of mental disorders and promotion of mental health and well-being are growing fields. Whether mental health promotion and prevention interventions provide value for money in children, adolescents, adults, and older adults is ...
Long Khanh-Dao Le, Adrian Cuevas Esturas, C. Mihalopoulos, Oxana Chiotelis, Jessica Bucholc, M. Chatterton, L. Engel   +6 more
semanticscholar   +1 more source

Cost-effectiveness analysis of olanzapine in four-drug antiemetic therapy in Japanese patients treated with highly emetogenic cisplatin-containing chemotherapy

Journal of Pharmaceutical Health Care and Sciences, 2022
Background Olanzapine has been shown to have an additive effect on the three-drug antiemetic therapy consisting of aprepitant, palonosetron, and dexamethasone, in a highly emetogenic cisplatin-containing chemotherapy.
Yu Kondo, Tomoya Tachi, Takayoshi Sakakibara, Jun Kato, Takahito Mizuno, Yoshio Miyake, Hitomi Teramachi   +6 more
doaj   +1 more source

Cost-effectiveness of Screening for Atrial Fibrillation Using Wearable Devices

JAMA Health Forum, 2022
Key Points Question Is population-based atrial fibrillation (AF) screening using wearable devices cost-effective? Findings In this economic evaluation of 30 million simulated individuals with an age, sex, and comorbidity profile matching the US ...
Wanyi Chen, S. Khurshid, Daniel E. Singer, S. Atlas, J. Ashburner, P. Ellinor, D. McManus, S. Lubitz, J. Chhatwal   +8 more
semanticscholar   +1 more source

Cost-effectiveness plane and Incremental Cost-Effectiveness Ratio of COTiD-UK vs TAU.

, 2022
Cost-effectiveness plane showing that the Incremental Cost-Effectiveness Ratio (ICER) of COTiD-UK vs TAU is always above the lower (£20,000 per QALY) and upper (£30,000 per QALY) willingness to pay threshold for a QALY.
Elena Pizzo (5980439), Jennifer Wenborn (4824852), Stephen Morris (324510), Jacqueline Mundy (9529284), Rumana Omar (447230), Martin Orrell (2616487), Jane Burgess (8177532), Michael King (42679)   +7 more
core   +1 more source

Industry sponsorship bias in cost effectiveness analysis: registry based analysis

British medical journal, 2022
Objective To assess the association between industry sponsorship (drug, medical device, and biotechnology companies) and cost effectiveness results in cost effectiveness analysis (CEA).
Feng Xie, Ting Zhou
semanticscholar   +1 more source

Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation [PDF]

, 2006
Background: The cost-effectiveness acceptability curve (CEAC) is a method for summarizing the uncertainty in estimates of cost-effectiveness. The CEAC, derived from the joint distribution of costs and effects, illustrates the (Bayesian) probability ...
Deborah A Marshall, Levy, Adrian R, Nichol, G., Fenwick Elisabeth, Adrian R Levy, Fenwick, E., Graham Nichol, Elisabeth Fenwick, Marshall, Deborah A, Nichol, Graham, Marshall, D.A., Levy, A.R., Levy Adrian R, Marshall Deborah A, Nichol Graham, Fenwick, Elisabeth   +15 more
core   +2 more sources

Method for adjusting results of pharmacoeconomic studies from country to country using Bayesian statistics [PDF]

Hospital Pharmacology, 2021
Introduction: Key problems when transferring results of pharmacoeconomic studies between countries are: relative infrequency of observational design, utilization of unreliable estimates of input parameters in many of modelling studies, not reporting ...
Janković Slobodan M., Kostić Marina J., Milovanović Jasmina R.   +2 more
doaj   +1 more source